Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
These numbers exceeded the Phase 2 results, partly because the trial ran longer (68 weeks versus 48 weeks) and partly because the dose escalation schedule was refined
The TRANSCEND-T2D-1 trial showed a 2.0% HbA1c reduction and 16.8% weight loss in 537 patients with type 2 diabetes over 40 weeks
More Mechanisms = More Potential Risks: Because Retatrutide is a triple agonist, it may come with more side effects and unknown long-term risks, including GI issues, nerve-related symptoms, and possible heart concerns
In contrast, during fasting and hypoglycemic conditions, GIP acts to increase glucagon secretion with little effect on insulin release
[12] [13] Readers should note that final peer-reviewed results from this programme are still emerging, and specific percentage figures may change as the full dataset is published
It is almost always temporary
US$ 27.75
US$ 27.18
US$ 20.07
US$ 23.74
US$ 20.19
